-
公开(公告)号:AU2008302448A1
公开(公告)日:2009-03-26
申请号:AU2008302448
申请日:2008-09-17
Applicant: ABBOTT LAB
Inventor: HAIGHT ANTHONY R , RANDOLPH JOHN T , LONGENECKER KENTON L , FRANCZYK THADDEUS S II , BETEBENNER DAVID A , DEGOEY DAVID A , STEWART KENT D , TUFANO MICHAEL D , LIU YAYA , WAGNER ROLF , SARRIS KATHY , LIU DACHUN , BARNES DAVID M , ROCKWAY TODD W , FLENTGE CHARLES A , KATI WARREN M , KOTECKI BRIAN J , ZHANG GEOFF G Z , CHEN SHUANG , GAO YI , HENRY RODGER F , HUANG PEGGY P , PRATT JOHN K , DONNER PAMELA L , MARING CLARENCE J , HUTCHINSON DOUGLAS K , KRUEGER ALLAN C , LOU XIAOCHUN , MOTTER CHRISTOPHER E , HENGEVELD JOHN E
IPC: C07D239/22 , A61K31/513 , A61P31/12 , C07D239/54 , C07D401/10 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia , inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; and (e) use of such compounds, salts, and compositions.
-
公开(公告)号:BR0315897A
公开(公告)日:2008-05-13
申请号:BR0315897
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D513/14 , C07D519/00
Abstract: The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided. formula (I)
-
公开(公告)号:PL376823A1
公开(公告)日:2006-01-09
申请号:PL37682303
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D519/00
-
公开(公告)号:AU2003291670A1
公开(公告)日:2004-06-07
申请号:AU2003291670
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04 , C07D519/00 , C07D513/14 , A61K31/554
Abstract: The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided. formula (I)
-
公开(公告)号:CO5261499A1
公开(公告)日:2003-03-31
申请号:CO00079306
申请日:2000-10-18
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , YU-GUI GU , HUI-JU CHEN , YUANWEI CHEN , DEGOEY DAVID A , FIOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , WARREN M KATI , KEMPF DALE J , APRIL L KENNEDY , KLEIN LARRY L , KRUEGER ALLAN C , ZHEN LIN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , KENT D STEWART , STOLL VINCENT S , MINGHUA SUN , NOAH P TU , WAGENAAR FRANK L , WANG GARY T , SHELDON WANG , WIEDEMAN PAUL E , YIBO XU , MING C YEUNG , CHEN ZHAO , STEOHEN HANESSIAN , MALKEN BAYRAKDARIAN , XUEHONG LUO
IPC: C07D401/12 , A61K31/16 , A61K31/341 , A61K31/357 , A61K31/381 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/405 , A61K31/415 , A61K31/4155 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/427 , A61K31/4439 , A61K31/5377 , A61K31/66 , A61K31/662 , A61P31/00 , A61P31/12 , A61P31/16 , A61P43/00 , C07D20060101 , C07D207/00 , C07D207/12 , C07D207/16 , C07D207/26 , C07D207/32 , C07D207/327 , C07D207/38 , C07D207/46 , C07D303/16 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D407/06 , C07D407/12 , C07D409/06 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/40 , C07F9/572
Abstract: Un compuesto enriquecido enantioméricamente CARACTERIZADO PORQUE tiene la estereoquímica absoluta de la fórmula: o una sal, un éster o una prodroga aceptable para uso farmacéutico de los mismosdonde R1 se selecciona del grupo formado por (a) -CO2H, (b) -CH2CO2H, (c) -SO3H, (d) -CH2SO3H, (e) -SO2H, (f) -CH2SO2H, (g) -PO3H2, (h) -CH2PO3H2, (i) -PO2H, o) -CH2PO2H, (k) tetrazolilo, (l) -CH2-tetrazolilo, (m) -C(=O)-NH-S(O)2-R11, (n) -CH2C(=O)-NH-S(O)2-R11, (o) -SO2N(T-R11)R12 y (p) -CH2SO2N(T-R11)R12donde T se selecciona del grupo formado por (i) un enlace, (ii) -C(=O)-, (iii) -C(=O)O-, (iv) -C(=O)S-, (v) -C(O)NR36, (vi) -C(=S)O-, (vii) -C(=S)S- y (viii) -C(=S)NR36-,R11 se selecciona del grupo formado por(i) C1-C12-alquilo, (ii) C2-C12 -alquenilo, (iii) cicloalquilo, (iv) (cicloalquil)alquilo, (v) (cicloalquil)alquenilo, (vi) cicloalquenilo, (vii) (cicloalquenil)alquilo, (viii) (cicloalquenil)alquenilo, (ix) arilo, (x) (aril)alquilo, (xi) (aril)alquenilo, (xii) heterocíclico, (xiii) alquilo(heterocíclico) y (xiv) alquenilo(heterocíclico); y R12 y R36 se selecionan independiente entre sí, del grupo formado - 2 -(i) hidrógeno, (ii) C1-C12-alquilo, (iii) C1-C12-alquenilo, (iv) cicloalquilo (v) (cicloalquil)alquilo, (vi) (cicloalquil)alquenilo, (vii) cicloalquenilo, (viii) (cicloalquenil)alquilo, (ix) (cicloalquenil)alquenilo, (x) arilo, (xi) (aril)alquilo, (xii) (aril)alquenilo, (xiii) heterocíclico, (xiv) alquilo (heterocíclico) y (xv) alquenilo(heterocíclico)X se selecciona del grupo formado por (a -C(=O)-N(R*)-, (b)-N(R*)-C(=O)-, (c)-C(=S)-N(R*)-, (d) -N(R*)-C(=S)-, (e)-N(R*)-SO2-, y M -SO2-N(R*)-, donde R* es hidrógeno, C1-C3-alquilo inferior o ciclopropilo, R2 se selecciona del grupo formado por (a) hidrógeno, (b) C1-C6-alquilo, (C) C2-C6-alquenilo, (d) C3C6 cicloalquilo, (e) C5-C6-cicloalquenilo, (f) halo-C1-C6-alquilo y (g) halo-C2-C6-alquenilo; o R2-X es donde Y1 es -CH2-, -O-, -S- o -NH- e Y2 es -C(=O)- o -C(Raa)(Rbb), donde Raa y Rbb se seleccionan, independientemente entre sí, del grupo formado por hidrógeno, C1-C3-alquilo inferior, hidroximetilo, 1 -hidroxietilo, 2-hidroxietilo, aminometilo, 1-aminoetilo, 2-aminoetilo, tiolmetilo, 1-tioletilo, 2-tioletilo, metoximetilo, N-metilaminometilo y metiltiometilo; R3 y R4 se seleccionan, independientemente entre sí, del grupo formado por (a) hidrógeno, (b) cicloalquilo, (c) cicloalquenilo, (d) heterocíclico, (e) arilo y (f) -Z-R14 donde Z es (i) -C(R37a)(R37b)-, (ii)-C(R47)=C(R48)-, (iii)-C=C-, (iv) -C(=O)-(v) -C(=S)-, (vi) -C(=NR15)-, (vii) -C(R37a)(OR37c)-, (viii) -C(R37a)(SR37c)-, (ix) -C(R37a)(N(R37b)(R37c))-, (x) -C(R37a)(R37b)-O-, (xi) -C(R37a)(R37b)-N(R37c)-, (xii) -C(R37a)(R37b)-N(O)(R37c), (xiii) -C(R37a)(R37b)-N(OH)-, (xiv) -C(R37a)(R37b)-S-, (xv) -C(R37a)(R37b)-S(O), (xvi) -C(R37a)(R37b)-S(O)2-, (xvii) -C(R37a)(R37b)-C(=O)-, (xviii) -C(R37a)(R37b)-C(=S)-, (xix) -C(R37a)(R37b)-C(=NR15)-, (xx) -C(R37a)(OR37c)-C(=O)-, (xxi) -C(R37a)(SR37b)-C(=O)-, (xxii) -C(R37a)(R37c)-C(=S)-, (xxiii) -C(R37a)(SR37c)-C(=S)-, (xxiv) -C(=O)-C(R37a)(OR37c)-, (xxv) -C(=O)-C(R37a)(SR37c)-, (xxvi) -C(=S)-C(R37a)(OR37c)-, (xxvii) -C(=S)-C(R37a)(SR37c)-, (xxviii) -C(R37a)(OR37c)-C(R37a)(OR37c)-, (xxix)-C(R37a)(SR37c)-C(R37a)(OR37c)-, (xxx) -C(R37a)(OR37c)-C(R37a)(SR37c)-, (xxxi) -C(R37a)(SR37c)-C(R37a)(SR37c)-, (xxxii) -C(=O)-C(=O)-, (xxxiii) -C(=S)-C(=S)-, (xxxiv) -C(=O)-O-, (xxxv) -C(=O)-S-, (xxxvi) -C(=S)-O-, (xxxvii) -C(=S)-S-, (xxxviii) -C(=O)-N(R37a)- (xxxix) -C(=S)-N(R37a)-, (xI) -C(R37a)(R37b)-C(=O)-N(R37a)-, (xli) -C(R37a)(R37b)-C(=S)-N(R37a)-, (xlii) -C(R37a (R37b)-C(=O)-O-, (xliii) -C(R37a)(R37b)-C(=O)-S-, (xliv) -C(R37a)(R37b)-C(=S)-O, (xlv) -C(R37a)(R37b)-C(=S)-S-, (xlvi) -C(37a)(R37b)N(R37b)-C(=O)-, (xlvii) -C(R37a)(R37b)-N(R37b)-C(=S)-, (xlviii) -C(R37a)(R37b)-O-C(=O)- (xlix) -C(R37a)(R37b)-S-C(=O)-, (l) -C(R37a)(R37b)-O-C(=S)-, (li) -C(R37a)(R37b)-S-C(=S)-, (Iii) -C(R37a)(R37b)-N(R37b)-C(=O)-N(R37a)-, (Iiii) -C(R37a)(R37b)-N(R37b)-C(=S)-N(R37a)-, (liv) -C(R37a)(R37b)-N(R37b)-C(=O)-O-, (Iv) -C(R37a) (R37b)-N(R37b)-C(=O)-S-, (Ivi) -C(R37a)(R37b)-N(R37b)-C(=S)-O-, (lvii) -C(R37a)(R37b)-N(R37b)-C(=S)-S-, (lviii) -C(R37a)(R37b)-O-C(=O)-N(R37a)-, (lix) -C(R37a)(R37b)-S-C(=O)-N(R37a)-, (Ix) -C(R37a)(R37b)-O-C(=S)-N(R37a)-, (Ixi) -C(R37a)(R37b)-S-C(=S)-N(R37a)-, (Ixii) -C(R37a)(R37b)-O-C(=O)-O-, (Ixiii) -C(R37a)(R37b)-S-C(=O)-O-, (Ixiv) -C(R37a)(R37b)-O-C(=O)-S-, (Ixv) -C(R37a)(R37b)-S-C(=O)-S-, (Ixvi) -C(R37a)(R37b)-O-C(=S)-O-, (Ixvii) -C(R37a)(R37b)-S-C(=S)-O-, (lxviii) -C(R37a)(R37b)-O-C(=S)-S-, (Ixix) -C(R37a)(R37b)-S-C(=S)-S- o (Ixx) -C(R37a)(R37b)-C(R37a)(OR37c); R14 es (i) hidrógeno, (ii) C1-CI2-alquilo, (iii) haloalquilo, (iv) hidroxialquilo, (v) alquilo tiol-sustituido, (vi) alquilo R37c-O-sustituido, (vii) alquilo R37c-S-sustituido, (viii) aminoalquilo, (ix) alquilo (R37C)NH-sustituido, (x) alquilo (R37a)(R37c)N- sustituido, (xi) alquilo R37aO-(O=)C-sustituido, (xii) alquilo R37a-S-(O=)C sustituido, (xiii) alquilo R37aO-(S=)C-sustituido, (xiv)alquilo R37a-S-(S=)C sustituido, (xv) alquilo (R37aO)2-P(=O)-sustituido, (xvi) cianoalquilo, (xvi)C1-C12- alquenilo, (xviii) haloalquenilo, (xix) C2-C12-alquinilo, (xx) cicloalquilo, (xxi) (cicloalquil)alquilo, (xxii) (cicloalquil)alquenilo, (xxiii) (cicloalquil)alquinilo, (xxiv) cicloalquenilo (xxv) (cicloalquenil) alquilo, (xxvi) - 3 -(cicloalquenil)alquenilo, (xxvii) (cicloalquenil)alquinilo, (xxviii) arilo, (xxix) (aril) alquilo, (xxx) (aril)alquenilo, (xxxi) (aril)alquinilo, (xxxii) heterocíclico, (xxxiii) alquilo (heterocíclico), (xxxiv) alquenilo(heterocíclico) o (xxxv) (heterocíclico)alquinilo, con la condición que R14 es distinto de hidrógeno cuando Z es -C(R37a)(R37b)-N(R37b)-C(=O)-(O)-, -C(R37a)(R37b)-N(R37b)-C(=S)-O-, -C(R37a)(R37b)-N(R37b)-C(=O)-O-, -C(R37a)(R37b)-N(R37b)-C(=S)-S-, -C(R37a)(R37b)-O-C(=O)-O-, -C(R37a)(R37b)-O-C(=S)-O-, -C(R37a)(R37b)-S-C(=O)-O-, -C(R37a)(R37b)-S-C(=S)-O-, -C(R37a)(R37b)-O-C(=O)-S-, -C(R37a)(R37b)-O-C(=S)-S-, C(R37a)(R37b)-S-C(=O)S o -C(R37a)R37b)-S-C(=S)-S-; R37a, R37b y R47 y R48 se seleccionan en cada aparición, independientemente entre sí, del grupo formado por (i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) hidroxialquilo, (v) alcoxialquilo, (vi) C2-C12-alquenilo, (vii) haloalquenilo, (viii) C2-C12-alquinilo, (ix) cicloalquilo, (x) (cicloalquil)alquilo, (xi) (cicloalquil)alquenilo, (xii) (cicloalquil)alquinilo, (xiii) cicloalquenilo, (xiv) (cicloalquenil) alquilo, (xv) (cicloalquenil)alquenilo, (xvi) (cicloalquenil)alquinilo, (xvii) arilo, (xviii) (aril)alquilo, (xix) (aril)alquenilo, (xx)(aril)alquinilo, (xxi)heterocíclico, (xxii) alquilo(heterocíclico), (xxiii) alquenilo(heterocíclico) y (xxiv) alquinilo(heterocíclico), R37c se selecciona en cada aparición, independientemente, del grupo formado por (i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) C2-C12-alquenilo, (v) haloalquenilo, (vi) C2-C12-alquinilo, (vii) cicloalquilo, (viii) (cicloalquil)alquilo, (ix) (cicloalquil)alquenilo, (x) (cicloalquil) alquinilo, (xi) cicloalquenilo, (xii) (cicloalquenil)alquilo, (xiii) (cicloalquenil)alquenilo, (xiv) (cicloalquenil)alquinilo, (xv) arilo, (xvi) (aril)alquilo, (xvii) (aril)alquenilo, (xviii) (aril)alquinilo, (xix) heterocíclico, (xx) alquilo(heterocíclico), (xxi) alquenilo(heterocíclico), (xxii) alquinilo (heterocíclico), (xxiii)-O(=O)-R14, (xxiv)-C(=S)-R, (xxv)-S(O)2-R14 y (xxvi) hidroxialquilo; o cuando Z es -C(R37a)(R37b)-N(R37c)-, entonces cuando N(R37c) y R14 se toman juntos constituyen un grupo azido; o cuando Z es -C(R37a)(R37b)-N(O)(R37c)-, entonces cuando N(O)(R37c) y R14 se toman juntos constituyen un anillo heterocíclico de 3-7 miembros N-oxidado que posee por lo menos un átomo de nitrógeno en el anillo N-oxidado, o cuando Z es -C(R37a)(OR37b)-, -C(R37a)(SR37c)-o- -C(R37a)(N(R37b)(R37c))-, entonces R37a, R14 y el átomo de carbono al que están unidos cuando se toman juntos forman un anillo ciclopentilo, ciclopentenilo, ciclohexilo o ciclohexenilo o entonces OR37c o SR37c o N(R37c) y R14 y el átomo de carbono al que están unidos cuando se toman juntos forman un anillo heterocíclico que contiene un átomo de O, S o N, respectivamente, y contiene entre 4 y 8 átomos del anillo; R15 se selecciona del grupo formado por (i) hidrógeno, (ii) hidroxi, (iii) amino, (iv) C1-C12-alquilo, (v) haloalquilo, (vi) C2-C12-alquenilo (vii) haloalquenilo, (viii) cicloalquilo (ix) (cicloalquil)alquilo, (x) (cicloalquil)alquenilo, (xi) cicloalquenilo, (xii) (cicloalquenil)alquilo, (xiii) (cicloalquenil)aIquenilo, (xiv) arilo, (xv) (aril)alquilo, (xvi)(aril)alquenilo, (xvii) heterocíclico, (xviii) alquilo(heterocíclico) y (xix) alquenilo(heterocíclico), o R3 y R4 tomados juntos, con el átomo al cual están unidos, forman un anillo carbocíclico o heterocíclico que posee de 3 a 8 átomos en el anillo, R5 se selecciona del grupo formado por (a) hidrógeno, (b) -CH(R38)2, (c) -O-R40, (d) C2-C4-alquinilo, (e) ciclopropilo, (f) ciclobutilo, (g) -C(=Q1)-R17 y (h) -N(R19)2 donde Q1 es O, S o N(R18); R17 y R18 se seleccionan Independientemente, en cada aparición, del grupo formado por hidrógeno, metilo y etilo; R19, R38 y R40 se seleccionan independientemente, en cada aparición, del grupo formado por (i) hidrógeno (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) C2-C12-alquenilo, (v) haloalquenilo, (vi) cicloalquilo, (vii) (cicloalquil)alquilo, (viii) (cicloalquil)alquenilo, (ix) cicloalquenilo, (x) (cicloalquenil)alquilo, (xi) (cicloalquenil)alquenilo, (xii) arilo, (xiii) (aril)alquilo (xiv) (aril)alquenilo, (xv) heterocíclico, (xvi) alquilo(heterocíclico) y (xvii) alquenilo(heterocíclico);Y se selecciona del grupo formado por - 4 -(a) hidrógeno, (b) C1-C5-alquilo, (c) C1-C5-haloalquilo, (d) C2-C5-alquenilo, (e) C2-C5-haloalquenilo, (f) C2-C5-alquinilo, (g) C3-C5-cicloalquilo, (h C3-C5-cicloalquil-C1-a-C3-alquilo, (i) C5-cicloalquenilo, (j) C5-cicloalquenil-C1-a-C3-alquilo, (k) C5-cicloa
-
公开(公告)号:SK15092000A3
公开(公告)日:2001-05-10
申请号:SK15092000
申请日:1999-04-12
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU GUI , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VICENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG GARY T , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572 , A61K31/40 , C07D407/04
-
公开(公告)号:AU8005100A
公开(公告)日:2001-04-30
申请号:AU8005100
申请日:2000-10-10
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GIRANDA VINCENT L , KEMPF DALE J , STOLL VINCENT S , SUN MINGHUA , ZHAO CHEN , GU YU GUI , WANG GARY T , KRUEGER ALLAN C , CHEN YUANWEI , DEGOEY DAVID A , GRAMPOVNIK DAVID J , KATI WARREN M , KENNEDY APRIL L , LIN ZHEN , MADIGAN DONALD L , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , WANG SHELDON , YEUNG MING C
IPC: A61K31/195 , C07C233/48 , C07C237/24 , C07C271/22 , C07C271/24 , C07C279/16 , C07D233/54 , C07D263/32 , C07D307/24 , C07D317/30 , C07D405/04 , C07C233/00
Abstract: Disclosed are compounds of the formula:which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.
-
公开(公告)号:CA2388859A1
公开(公告)日:2001-04-26
申请号:CA2388859
申请日:2000-10-10
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , WAGENAAR FRANK L , WANG SHELDON , GIRANDA VINCENT L , LIN ZHEN , FLOSI WILLIAM J , DEGOEY DAVID A , KLEIN LARRY L , KEMPF DALE J , STOLL VINCENT S , KATI WARREN M , GRAMPOVNIK DAVID J , KENNEDY APRIL L , WIEDEMAN PAUL E , MCDANIEL KEITH F , TU NOAH P , XU YIBO , HANESSIAN STEPHEN , STEWART KENT D , SHAM HING L , MUCHMORE STEVEN W , WANG GARY T , BAYRAKDARIAN MALKEN , LUO XUEHONG , CHEN YUANWEI , MADIGAN DAROLD L , YEUNG MING C , ZHAO CHEN , KRUEGER ALLAN C , GU YU GUI , CHEN HUI-JU , SUN MINGHUA
IPC: C07D401/12 , A61K31/357 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/405 , A61K31/415 , A61K31/4155 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/427 , A61K31/4439 , A61K31/5377 , A61K31/66 , A61K31/662 , A61P31/00 , A61P31/12 , A61P31/16 , A61P43/00 , C07D20060101 , C07D207/00 , C07D207/12 , C07D207/16 , C07D207/26 , C07D207/32 , C07D207/327 , C07D207/38 , C07D207/46 , C07D303/16 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D407/06 , C07D407/12 , C07D409/06 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/40 , C07F9/572
Abstract: Enantiomerically enriched compounds having the absolute stereochemistry of t he formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.
-
公开(公告)号:CZ20003872A3
公开(公告)日:2001-03-14
申请号:CZ20003872
申请日:1999-04-12
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU-GUI , CHEN HUI-YU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG GARY T , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/40 , A61P31/16 , C07D207/16 , C07D401/12 , C07D403/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D417/04
-
公开(公告)号:BR9909870A
公开(公告)日:2000-12-19
申请号:BR9909870
申请日:1999-04-12
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU-GUI , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572 , A61K31/40 , C07D407/04
-
-
-
-
-
-
-
-
-